Product Description: Alirocumab (REGN 727) is a human monoclonal antibody inhibitor of PCSK9. Alirocumab is a monoclonal antibody. Alirocumab has anti-inflammatory, antiangiogenic and antioxidant effects. Alirocumab can be used in the study of hypercholesterolemia[1][2][3][4][5].
Applications: Metabolism-protein/nucleotide metabolism
Formula: N/A
References: [1]Ni X, et al. Establishment of an in vitro safety assessment model for lipid-lowering drugs using same-origin human pluripotent stem cell-derived cardiomyocytes and endothelial cells. Acta Pharmacol Sin. 2022 Jan;43(1):240-250./[2]Kühnast S, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res. 2014 Oct;55(10):2103-12./[3]Huang HC, et al. Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats. Int J Mol Sci. 2022 Jul 2;23(13):7378./[4]Tavori H, et al. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1137-44./[5]Markham A. Alirocumab: First Global Approval. Drugs. 2015;75(14):1699-1705.
CAS Number: 1245916-14-6
Molecular Weight: N/A
Compound Purity: 97.00
Research Area: Cardiovascular Disease
Solubility: H2O
Target: PCSK9
English
Deutsch
